Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone enanthate versus testosterone undecanoate for metabolic effects in transgender men
TCTR20260223009Phase 4Recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in gender dysphoria (GD) comparing Testosterone enanthate with Testosterone undecanoate (2 arms). Primary endpoint: HDL cholesterol level changes. Started May 2025; status: recruiting.
02
Drugs
testosterone enanthatetestosterone undecanoate
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on TCTR20260223009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260223009.